Takuya Matsui

Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia

Yosuke Ogoshi, Takuya Matsui, Ikuo MITANI et al. · ACS Medicinal Chemistry Letters · 2017 · 50 citations · Full text

Development of Inhalable Nanocrystalline Solid Dispersion of Tranilast for Airway Inflammatory Diseases

Satomi Onoue, Yosuke Aoki, Yohei Kawabata et al. · Journal of Pharmaceutical Sciences · 2010 · 43 citations · Full text

Materials Science, Nanomedicine, Engineering +7

JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor

Kenji Fukui, Yuichi Shinozaki, Hatsue Kobayashi et al. · European Journal of Pharmacology · 2019 · 43 citations

Inflammation, Endothelial Cell Pathobiology, Induces Erythropoiesis +11

ESTABLISHMENT AND CHARACTERIZATION OF A HUMAN B CELL LINE FROM THE LUNG TISSUE OF A PATIENT WITH SCLERODERMA; EXTRAORDINARY HIGH LEVEL OF IL-6 SECRETION BY STIMULATED FIBROBLASTS

Kazuo Kondo, Tadashi Okada, Takuya Matsui et al. · Cytokine · 2001 · 41 citations

Inflammation, Cytokine, Inflammatory Lung Disease +14

Discovery of 6-Phenylpyrimido[4,5-<i>b</i>][1,4]oxazines as Potent and Selective Acyl CoA:Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitors with in Vivo Efficacy in Rodents

Brian M. Fox, Kazuyuki Sugimoto, Kiyosei Iio et al. · Journal of Medicinal Chemistry · 2014 · 30 citations · Full text

Vivo Efficacy, Pharmacotherapy, Selective Acyl Coa +20